Inulin and S. Salivarius Reduce Halitosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02794766 |
Recruitment Status :
Completed
First Posted : June 9, 2016
Results First Posted : August 19, 2020
Last Update Posted : August 19, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Halitosis Tongue Diseases | Drug: Inulin+SS Drug: S salivarius Drug: Placebo | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Inulin and Streptococcus Salivarius Reduce Halitosis Associated With Tongue Coating: A Randomized Clinical Trial |
Study Start Date : | March 2014 |
Actual Primary Completion Date : | May 2015 |
Actual Study Completion Date : | November 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Inulin+SS
Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
|
Drug: Inulin+SS
Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
Other Name: Inulin plus Streptococcus salivarius |
Active Comparator: S salivarius
Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
|
Drug: S salivarius
Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
Other Name: Streptococcus salivarius |
Placebo Comparator: Placebo
Placebo 1 gum per oral each 12 hours, for 10 days
|
Drug: Placebo
Placebo 1 gum each 12 hours for 10 days |
- Halitosis Measured by Organoleptic Test [ Time Frame: Halitosis measured by organoleptic test was performed before and 14 days after the treatments ]Unabbreviated scale title: Organoleptic test Minimum: 0 Maximum: 5 Higher score means worse outcome.
- Coating Index [ Time Frame: Coating index was evaluted before and 14 days after the treatments. ]Unabbreviated scale title: Coating index (evaluated by a trained judge during oral examination) Minimum: 0 Maximum: 4 Higher score means worse outcome.
- Halitosis Measured by Halimeter [ Time Frame: Halitosis measured by halimeter test was performed before and 14 days after the treatments ]Unabbreviated scale title: Halitosis measured by halimeter Minimum: 0 Maximum: 500 A score =>75 ppb means halitosis.
- Oral-health Related Quality of Life [ Time Frame: Oral health impact profile -14 questionnaire was filled before and 14 days after the treatments ]Unabbreviated scale title: Oral-health related quality of life measured by Oral Health Impact Profile -14 questionnaire Manimum: 0 Maximum: 56 Higher scores mean worse outcome

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- adult patients with halitosis by tongue coating;
- participants must accept to participate in the study;
- tongue coating identified by oral examination;
- halitosis must be confirmed by the organoleptic test.
Exclusion Criteria:
- halitosis for other conditions, including periodontal diseases and non-oral conditions;
- use of antibiotics in the last 30 days;
- active smoking (>10 cigarettes/day);
- alcohol consumption (>2 drinks/day);
- report of pregnancy or breastfeeding;
- report of systemic diseases, including diabetes, kidney failure and hepatic cirrhosis.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02794766
Principal Investigator: | Fernando Fornari | Universidade de Passo Fundo |
Responsible Party: | Fernando Fornari, Professor, Universidade de Passo Fundo |
ClinicalTrials.gov Identifier: | NCT02794766 |
Other Study ID Numbers: |
CAAE40334914000005342 |
First Posted: | June 9, 2016 Key Record Dates |
Results First Posted: | August 19, 2020 |
Last Update Posted: | August 19, 2020 |
Last Verified: | August 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Tongue Diseases Halitosis Signs and Symptoms, Digestive Mouth Diseases Stomatognathic Diseases |